Back to MetLife Investment Management, LLC MetLife Investment Management, LLC

IMVTIMVT

Showing 8 of 25 quarters

Position history for MetLife Investment Management, LLCMetLife Investment Management, LLC's holdings in Immunovant, Inc.

Yes. MetLife Investment Management holds 49,677 shares of IMVT (Immunovant), worth $1.9M, as of its Q2 2026 13F filing. It increased the position by 5,216 shares (+11.7%) from Q1 2026. MetLife Investment Management has held IMVT since Q3 2022, across 16 quarterly 13F filings.

Current Value

$1.9M

Current Shares

49,677

Total Value Change

+$955,891

Total Shares Change

+16,069

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
49,677
+11.7%
$1.9M0.0%$38.53
29
2026-Q1
Increased
44,461
+13.9%
$1.1M0.0%$24.84
29
2025-Q4
Decreased
39,036
-4.6%
$992,2950.0%$25.42
0
2025-Q3
Unchanged
40,900
0.0%
$659,3080.0%$16.12
0
2025-Q2
Increased
40,900
+16.5%
$654,4000.0%$16.00
28
2025-Q1
Decreased
35,095
-1.6%
$599,7740.0%$17.09
0
2024-Q4
Increased
35,648
+6.1%
$883,0010.0%$24.77
26
2024-Q3
Unchanged
33,608
0.0%
$958,1640.0%$28.02
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used